Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Neuroprotective effect of masitinib in rats with postischemic stroke.
Physiopathological Roles of p2x Receptors in the Central Nervous System.
Persistence on therapy and propensity matched outcome comparison of two subcutaneous interferon Beta 1a dosages for multiple sclerosis.
Saccadic intrusions: review and update.
Differential effects of fingolimod on B-cell populations in multiple sclerosis.
Immunological Markers for PML Prediction in MS Patients Treated with Natalizumab.
Sanofi withdraws Campath in US and EU
Teva announces FDA acceptance of sNDA for a higher concentration dose of COPAXONE® given three times a week
Induction of pathogenic TH17 cells by inducible salt-sensing kinase SGK1.
Increased CD8+ T Cell Response to Epstein-Barr Virus Lytic Antigens in the Active Phase of Multiple Sclerosis.
Restoration of axon conduction and motor deficits by therapeutic treatment with glatiramer acetate.
Reduction of disease activity and disability with high-dose cyclophosphamide in patients with aggressive multiple sclerosis.
Safety issue puts daclizumab in doubt for MS
Daclizumab for relapsing remitting multiple sclerosis.
Fatal toxic epidermal necrolysis in a patient on teriflunomide treatment for relapsing multiple sclerosis.
Effects of Inhibitors of the Renin-Angiotensin System on the Efficacy of Interferon beta-1b: A post hoc Analysis of the BEYOND Study.
Chemistry, toxicology, pharmacology and pharmacokinetics of idebenone: a review.
Title: Pharmacokinetics and Pharmacodynamics of Peginterferon Beta-1a in Patients with Relapsing-Remitting Multiple Sclerosis in the Randomised ADVANCE Study.
Testing for urinary tract colonisation before high-dose corticosteroid treatment in acute multiple sclerosis relapses: prospective algorithm validation.
Lack of efficacy of mitoxantrone in primary progressive Multiple Sclerosis irrespective of pharmacogenetic factors: A multi-center, retrospective analysis.
Cytotoxicity, DNA cross-linking, and single strand breaks induced by activated cyclophosphamide and acrolein in human leukemia cells.
Axonal and oligodendrocyte-localized IgM and IgG deposits in MS lesions.
The two faces of neuromyelitis optica.
Autologous attenuated T-cell vaccine (Tovaxin) dose escalation in multiple sclerosis relapsing-remitting and secondary progressive patients nonresponsive to approved immunomodulatory therapies.
B-cell reconstitution and BAFF after alemtuzumab (Campath-1H) treatment of multiple sclerosis.

Pages